Chinese technology company responds to lawsuit in the United States, wins completely!
Chinese companies' overseas intellectual property rights protection has added another typical winning case. Recently, after nearly three years of cross-border patent litigation, Gongjing Technology (Jiaxing) Co., Ltd. (hereinafter referred to as "Gongjing Technology") has won the US patent dispute with Kaneka Corporation in Japan. The Federal District Court for the Eastern District of New York ruled that the core patent claims involved are invalid and completely rejected the infringement allegations of Japanese company Zhongyuan.
This victory not only cleared the intellectual property barriers for domestically produced coenzyme Q10 products to be exported to the United States, effectively safeguarding the legitimate rights and interests of Chinese enterprises in independent technology, but also provided a valuable demonstration for domestic scientific and technological innovation enterprises to participate in international competition in accordance with regulations and respond to malicious overseas intellectual property claims.
Fearless of cross-border litigation pressure, adhering to self-developed technology, actively safeguarding rights
In October 2023, Japanese company Zhongyuan filed a lawsuit with the Federal District Court for the Eastern District of New York, claiming that CrysQnol, a core product of reduced coenzyme Q10 under Eutectic Technology ™ (Original brand name Crystal QH) ®）， Infringement of claims 5 and 15 of US patent US 7829080 held by him. Unlike ordinary product trade disputes, this case is a professional game centered around the effectiveness of core technology and intellectual property boundaries, directly related to whether domestically developed products are restricted from entering the US market.
The patent litigation in the United States has always been characterized by complex procedures, long trial cycles, high litigation costs, and uncertain outcomes, which are major challenges faced by Chinese enterprises going global. At the beginning of the case, Gongjing Technology faced dual pressures: at the legal level, it needed to quickly establish a professional team for internal and external collaboration, coordinate a series of complex tasks such as technical disassembly, evidence sorting, expert argumentation, and cross-border litigation; At the commercial level, pending patent lawsuits have raised concerns among US market partners, distributors, and brand manufacturers about cooperation, directly affecting the progress of product overseas market layout.
Faced with pressure, after comprehensive evaluation of various solutions such as settlement and litigation, the enterprise ultimately chose to respond positively and protect its rights in accordance with regulations.
In this case, the relevant patent claims claimed by Japanese company Zhongyuan involve the natural impurity CoQ11 contained in reduced coenzyme Q10, and claim that regardless of the content of this component, it can exert a stabilizing effect on reduced coenzyme Q10. Under our effective defense, the court focused on examining the effectiveness and basis of this core technology, and found that Japan's Zhongyuan Company failed to prove that it already had the technical and scientific basis that matched the scope of the relevant claims at the time of the 2007 patent application, and the disclosed embodiments of the patent were not sufficient to support such a broad range of claims. ”The person in charge of eutectic technology said in an interview with reporters.
After detailed factual investigation by the court, expert evidence, witness cross examination, and multiple rounds of legal arguments and technical comparisons between the two parties, the Federal District Court for the Eastern District of New York finally made a key judgment, determining that the two core claims of the patent in question were declared invalid in accordance with the law due to lack of practicality, insufficient disclosure, and lack of enforceability.
The person in charge of eutectic technology stated that this dispute concerns the international fair competition rights of the company's independently developed technology, and is not simply a cost-benefit issue. If science and technology innovation enterprises choose to compromise and give up their self-developed technology route due to complex overseas patent litigation, it will not only restrict the long-term development of the enterprise, but also squeeze the overseas survival space of domestic innovative technologies. We insist on following the judicial procedures of the United States, relying on objective evidence and international rules to prove our innocence, and adhering to the core bottom line of independent innovation
Facing international competition and competing on the same stage in the rule system
This victory is a landmark case of Chinese enterprises in the field of functional raw materials going to the United States to protect their rights, breaking away from the passive response to disputes by Chinese enterprises going abroad in the past, and providing important reference for the industry to carry out global operations in compliance and respond to overseas intellectual property accountability.
The principle we have always adhered to throughout the entire case is to refuse to avoid international competition, but to participate in competition within international rules, "said the person in charge of Gongjing Technology.
In the eyes of industry insiders, the core value of this case lies in confirming that Chinese enterprises have entered a new stage of "technology going global" from traditional "product going global". In the past, domestic enterprises mainly focused on goods trade when going abroad. Nowadays, science and technology innovation enterprises represented by eutectic technology, with completely independent and controllable core technologies, deeply participate in mainstream market competition in Europe and America, face the intellectual property game of international leading enterprises, and complete authoritative verification of their own technological innovation and legality through overseas judicial systems, truly achieving fair competition with international industry leaders.
After nearly three years of long litigation battles, the winning verdict has made the entire team feel relieved and determined. Since the self litigation, all staff members of Gongjing Technology have been deeply involved in evidence preparation, technical demonstration, legal defense and other work, and have withstood the comprehensive test of cross-border litigation. This victory is not the end of development, but a new starting point for the company's self-developed technology to obtain international judicial recognition, further strengthening the company's determination to continue to deepen technology research and development, improve its independent intellectual property system, and layout the global market. "said the relevant person in charge of Gongjing Technology.
This verdict has been implemented, completely clearing CrysQnol ™ The intellectual property risks associated with the entry of reduced coenzyme Q10 into the US market pave the way for the large-scale development of the product in North America and the global market. Relying on independently developed core technologies, the enterprise continues to deepen its product research and upgrading. Currently, eutectic technology is still deeply engaged in CrysQnol ™ The scientific research on reduced coenzyme Q10 has completed the exploration of its bioavailability in human clinical efficacy verification. Large scale human clinical trials are being planned and promoted in an orderly manner, continuously consolidating the core competitiveness of the product with solid scientific data.
The person in charge of Gongjing Technology stated that in the future, the company will continue to adhere to independent innovation, increase efforts in core technology research and development and intellectual property layout, strictly abide by market rules and international economic and trade norms of various countries, continue to participate in global market competition with its own technology, build a global brand of China's own raw material technology, and provide reference for more overseas Chinese enterprises to adhere to innovation bottom line and protect their rights in accordance with regulations.